
    
      To determine the maximum tolerated dose of intravenous estramustine phosphate combined with
      Taxol.

      To estimate the complete and partial response rates to treatments with intravenous
      estramustine phosphate combined with Taxol in the treatment of hormone-refractory
      adenocarcinoma of the prostate.

      To determine the qualitative and quantitative toxicity of the combination of intravenous
      estramustine phosphate and Taxol.
    
  